Tenofovir Disoproxil Fumarate (TDF) and Lamivudine (3TC) are both antiretroviral medications used in the treatment of HIV (human immunodeficiency virus) infection. When combined in a single tablet, it is often prescribed as a fixed-dose combination to simplify the treatment regimen for individuals living with HIV. This combination is effective in inhibiting the replication of the virus.
Here are some key points about Tenofovir Disoproxil Fumarate 300 mg and Lamivudine 300 mg tablets:
Tenofovir Disoproxil Fumarate (TDF):
Lamivudine (3TC):
Key points about the combination (Tenofovir Disoproxil Fumarate 300 mg and Lamivudine 300 mg tablets):
Indications: This combination is used for the treatment of HIV-1 infection in adults and pediatric patients.
Dosage: The typical dosage involves taking one tablet orally once daily. The specific dosage may vary depending on the individual's health condition and the overall HIV treatment plan prescribed by a healthcare professional.
Adherence: Consistent adherence to the prescribed regimen is crucial for the effectiveness of HIV treatment. Missing doses or not taking the medication as directed can lead to reduced efficacy and the development of drug resistance.
Side Effects: Like any antiretroviral therapy, this combination can have potential side effects. Common side effects may include nausea, headache, and fatigue. It's important to report any severe or persistent side effects to a healthcare provider.
Pregnancy: These medications may be used during pregnancy, but the decision should be made in consultation with a healthcare provider, considering the potential risks and benefits.
It's important to note that the information provided here is general, and individual circumstances may vary. Always follow the guidance of your healthcare provider and inform them of any concerns or side effects you may experience during your treatment.